Verve Therapeutics is at the forefront of gene-editing technology applied to cardiovascular diseases. The company’s lead asset, VERVE-102, targets PCSK9 to reduce LDL cholesterol levels in patients ...
In a major shift, Editas has pivoted its focus towards in vivo gene editing, particularly targeting liver and hematopoietic stem cells (HSCs). This strategic move comes after the company terminated ...
Verve Therapeutics is at the forefront of developing one-time gene editing treatments for cardiovascular diseases. The company’s innovative approach aims to address the limitations of current ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する